RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria Transcript

Core Points - The company held a conference call to discuss a press release and accompanying slides available on its website [1] - Key executives present included the CEO, Chief Medical Officer, Chief Financial Officer, and a special guest from a medical research institute [2] - The call included forward-looking statements that are subject to risks and uncertainties, with a reminder to review risk factors in the latest quarterly report [3]